Keybank National Association OH Purchases Shares of 840 Insulet Co. (NASDAQ:PODD)

Keybank National Association OH acquired a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 840 shares of the medical instruments supplier’s stock, valued at approximately $219,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC raised its holdings in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the 4th quarter valued at $36,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares in the last quarter. Finally, Friedenthal Financial acquired a new stake in shares of Insulet in the 4th quarter valued at $57,000.

Analyst Ratings Changes

Several brokerages recently commented on PODD. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target on the stock. Canaccord Genuity Group lifted their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Citigroup lifted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Finally, StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $292.06.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.47% of the stock is owned by insiders.

Insulet Stock Up 3.5 %

Shares of NASDAQ:PODD opened at $245.35 on Wednesday. The company has a market cap of $17.23 billion, a price-to-earnings ratio of 42.37, a PEG ratio of 3.62 and a beta of 1.29. The firm’s 50-day simple moving average is $273.25 and its 200-day simple moving average is $254.12. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities research analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.